New combo aims to shield bone marrow in tough lung cancer cases
NCT ID NCT06992739
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether giving trilaciclib before sacituzumab tirumotecan can protect bone marrow in patients with advanced EGFR-mutated non-small cell lung cancer that has stopped responding to standard treatments. About 49 participants will receive the drug combo and be monitored for side effects like low blood cell counts and infections. The goal is to see if this approach reduces severe neutropenia and other blood-related toxicities.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trilaciclib and Sacituzumab Tirumotecan
- What this could lead to
- If successful, this could show that giving trilaciclib before sacituzumab tirumotecan reduces severe side effects like low white blood cell counts, making treatment safer for patients with advanced lung cancer.
- What could go wrong
- This is a small, early-phase trial with only 49 participants, so results may not apply to all patients. The combination may still cause side effects or not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, Fujian, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?
- Can a Two-Drug combo outsmart tough lung cancer?
- Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Drug duo aims to tackle tough lung cancers after first treatment fails
- Blood test may let cancer patients take safe breaks from immunotherapy